{"data":[{"accessionNo":"0000935836-26-000399","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J201","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"LYTTON LAURENCE W","reportingCik":null,"personType":"IN","sharesOwned":390807,"percentOfClass":3.2,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0000902664-26-002544","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J201","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Ryan Wilder","reportingCik":null,"personType":"HC,IN","sharesOwned":22654832,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0000902664-26-002544","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J201","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Vestal Point Capital, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":22654832,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001493152-26-019073","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Orin Hirschman","reportingCik":null,"personType":"HC,IN","sharesOwned":1186294,"percentOfClass":9.9,"filedAt":"2026-04-27","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001493152-26-019073","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"AIGH Capital Management LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":1186294,"percentOfClass":9.9,"filedAt":"2026-04-27","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0002050709-26-000012","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock","eventDate":"2026-03-30","reportingPerson":"Squadron Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":1271081,"percentOfClass":9.9,"filedAt":"2026-04-07","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0002050709-26-000012","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock","eventDate":"2026-03-30","reportingPerson":"Squadron Capital Management LLC","reportingCik":null,"personType":"IA,HC","sharesOwned":1271081,"percentOfClass":9.9,"filedAt":"2026-04-07","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0002050709-26-000012","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock","eventDate":"2026-03-30","reportingPerson":"William Blank","reportingCik":null,"personType":"IN,HC","sharesOwned":1271081,"percentOfClass":9.9,"filedAt":"2026-04-07","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0002050709-26-000012","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock","eventDate":"2026-03-30","reportingPerson":"Matthew Sesterhenn","reportingCik":null,"personType":"HC,IN","sharesOwned":1271081,"percentOfClass":9.9,"filedAt":"2026-04-07","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001213900-26-038610","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock","eventDate":"2026-04-01","reportingPerson":"Soleus Private Equity Fund III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1271080,"percentOfClass":9.99,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001213900-26-038610","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock","eventDate":"2026-04-01","reportingPerson":"Soleus Private Equity GP III, LLC","reportingCik":null,"personType":"OO","sharesOwned":1271080,"percentOfClass":9.99,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001213900-26-038610","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock","eventDate":"2026-04-01","reportingPerson":"Soleus PE GP III, LLC","reportingCik":null,"personType":"OO","sharesOwned":1271080,"percentOfClass":9.99,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001213900-26-038610","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock","eventDate":"2026-04-01","reportingPerson":"Soleus Capital Master Fund, L.P.","reportingCik":null,"personType":"FI","sharesOwned":1271080,"percentOfClass":9.99,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001213900-26-038610","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock","eventDate":"2026-04-01","reportingPerson":"Soleus Capital, LLC","reportingCik":null,"personType":"OO","sharesOwned":1271080,"percentOfClass":9.99,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001213900-26-038610","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock","eventDate":"2026-04-01","reportingPerson":"Soleus Capital Group, LLC","reportingCik":null,"personType":"OO","sharesOwned":1271080,"percentOfClass":9.99,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001213900-26-038610","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock","eventDate":"2026-04-01","reportingPerson":"Soleus Capital Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1271080,"percentOfClass":9.99,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001213900-26-038610","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock","eventDate":"2026-04-01","reportingPerson":"Soleus GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":1271080,"percentOfClass":9.99,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001213900-26-038610","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":"03836J102","securityClass":"Common Stock","eventDate":"2026-04-01","reportingPerson":"Guy Levy","reportingCik":null,"personType":"IN","sharesOwned":1271080,"percentOfClass":9.99,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001104659-26-015324","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":null,"securityClass":"Common stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":411520,"percentOfClass":4.5,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001104659-26-015324","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":null,"securityClass":"Common stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":411520,"percentOfClass":4.5,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001104659-26-015324","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":null,"securityClass":"Common stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":411520,"percentOfClass":4.5,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001493152-26-003971","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Orin Hirschman","reportingCik":null,"personType":"HC,IN","sharesOwned":651747,"percentOfClass":9.9,"filedAt":"2026-01-28","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001493152-26-003971","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"AIGH Capital Management LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":651747,"percentOfClass":9.9,"filedAt":"2026-01-28","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0000935836-25-000708","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-13","reportingPerson":"LYTTON LAURENCE W","reportingCik":null,"personType":"IN","sharesOwned":681837,"percentOfClass":9.9,"filedAt":"2025-11-17","canonicalUrl":"https://xoomar.com/markets/stocks/apre"},{"accessionNo":"0001214659-25-016261","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001781983","issuerName":"Aprea Therapeutics, Inc.","ticker":"APRE","cusip":null,"securityClass":"Common stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Sio Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":112223,"percentOfClass":1.93,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/apre"}],"updatedAt":"2026-11-04T04:19:59.869Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/apre","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}